In a new paper from the lab we show that engineered SOX17 and miniSOX not only replace but outperform SOX2 in driving derivation of induced expanded potential stem cells - a platform to model early development and discover new antiviral and anti‑ageing therapies.
đź”— www.nature.com/articles/s42...
Engineered SOX17 factors, including a miniaturized variant, replace SOX2 to drive efficient direct reprogramming to induced human expanded potential stem cells under feeder-based and feeder-free cultu...